PMID- 19616866
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20181201
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 68
IP  - 2
DP  - 2010 May
TI  - Assessment of mean EGFR gene copy number is a highly reproducible method for 
      evaluating FISH in histological and cytological cancer specimens.
PG  - 192-7
LID - 10.1016/j.lungcan.2009.06.019 [doi]
AB  - The aims of this study were first, to systematically assess the inter-observer 
      reproducibility of mean Epidermal Growth Factor Receptor (EGFR) gene copy number 
      (MCN) in histological and cytological specimens from lung and non-lung cancers, 
      second to compare the performance of this quantitative approach to the current 
      Colorado criteria for the assessment of fluorescence in situ hybridization (FISH) 
      positivity and third to develop a model to convert cytology into histology MCN. 
      EGFR FISH analysis was performed on 170 histological and 153 cytological 
      specimens. The MCN and Colorado criteria were assessed by two independent 
      observers and agreement evaluated using Bland-Altman plots and kappa values. 
      Conversion of cytology into histology MCN was tested on two randomized subgroups 
      of specimens. Applying the Colorado criteria, agreement between observers was 
      moderate with histology (k=0.5) and excellent with cytology (k=0.94). Positivity 
      in histology versus cytology led to fair agreement (k=0.33). MCN was 
      significantly greater in cytology compared to histology (p<0.001) with excellent 
      inter-observer agreement in both sample types (r=0.99 and 0.89, respectively). 
      The average difference in MCN between observers was -0.003 (95%CI: -0.05 to 0.05) 
      and 0.008 (95%CI: -0.09 to 0.11) for cytology and histology, respectively. A 
      reliable conversion model with an R(2)-value of 0.91 in the validation subgroup 
      (p<0.001) was obtained. The MCN is a reproducible scoring method for evaluating 
      EGFR FISH in samples from lung and non-lung cancers. This quantitative scoring 
      system may constitute an alternative to current methods of gene copy number 
      assessment and will further help to optimize patient selection for targeted 
      therapies.
CI  - Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
FAU - Zlobec, Inti
AU  - Zlobec I
AD  - Institute for Pathology, University of Basel, Schonbeinstrasse 40, Basel 4031, 
      Switzerland.
FAU - Raineri, Ines
AU  - Raineri I
FAU - Schneider, Sandra
AU  - Schneider S
FAU - Schoenegg, Rene
AU  - Schoenegg R
FAU - Grilli, Bruno
AU  - Grilli B
FAU - Herzog, Michelle
AU  - Herzog M
FAU - Savic, Spasenija
AU  - Savic S
FAU - Bubendorf, Lukas
AU  - Bubendorf L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090718
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenocarcinoma/*diagnosis/epidemiology/genetics/pathology/physiopathology
MH  - Diagnosis, Differential
MH  - Disease Progression
MH  - ErbB Receptors/*genetics
MH  - Feasibility Studies
MH  - *Gene Dosage
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*diagnosis/epidemiology/genetics/pathology/physiopathology
MH  - Observer Variation
MH  - Predictive Value of Tests
EDAT- 2009/07/21 09:00
MHDA- 2010/09/08 06:00
CRDT- 2009/07/21 09:00
PHST- 2009/05/15 00:00 [received]
PHST- 2009/06/17 00:00 [revised]
PHST- 2009/06/20 00:00 [accepted]
PHST- 2009/07/21 09:00 [entrez]
PHST- 2009/07/21 09:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
AID - S0169-5002(09)00374-2 [pii]
AID - 10.1016/j.lungcan.2009.06.019 [doi]
PST - ppublish
SO  - Lung Cancer. 2010 May;68(2):192-7. doi: 10.1016/j.lungcan.2009.06.019. Epub 2009 
      Jul 18.